{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:33:57Z","timestamp":1761237237321},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,7,21]],"date-time":"2005-07-21T00:00:00Z","timestamp":1121904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00262-005-0032-7","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T20:00:14Z","timestamp":1121889614000},"page":"221-228","source":"Crossref","is-referenced-by-count":5,"title":["Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?"],"prefix":"10.1007","volume":"55","author":[{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Johan","family":"Tronstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,7,21]]},"reference":[{"key":"32_CR1","first-page":"2213","volume":"30","author":"HT Abelson","year":"1970","unstructured":"Abelson HT, Rabstein LS (1970) Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res 30:2213\u20132222","journal-title":"Cancer Res"},{"key":"32_CR2","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood.V96.6.2240","volume":"96","author":"A Aguayo","year":"2000","unstructured":"Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O\u2019Brien S, Keating M, Freireich E, Albitar M (2000) Angiogenesis in acute and chronic leukemia and myelodysplastic syndromes. Blood 96:2240\u20132245","journal-title":"Blood"},{"key":"32_CR3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/sj.leu.2402201","volume":"15","author":"JB Almond","year":"2001","unstructured":"Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM (2001) Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an approximately 700\u00a0kDa Apaf-1 containing apoptosome complex. Leukemia 15:1388\u20131397","journal-title":"Leukemia"},{"key":"32_CR4","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S1357-2725(02)00068-7","volume":"34","author":"A August","year":"2002","unstructured":"August A, Fischer A, Hao S, M\u00fcller C, Ragin M (2002) The Tec family of tyrosine kinases in T cells, amplifiers of T cell receptor signals. Int J Biochem Cell Biol 34:1184\u20131189","journal-title":"Int J Biochem Cell Biol"},{"key":"32_CR5","first-page":"33","volume":"7","author":"L Bai","year":"2000","unstructured":"Bai L, Kon K, Tatsumi M, Ito H, Hayashi S, Brautigam M (2000) A human B-cell CLL model established by transplantation of JOK-1 cells into SCID mice and an anti-leukemia efficacy of fludarabine phosphate. Oncol Rep 7:33\u201338","journal-title":"Oncol Rep"},{"key":"32_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0145-2126(03)00256-X","volume":"28","author":"O Bairey","year":"2004","unstructured":"Bairey O, Boycov O, Kaganovsky E, Zimra Y, Shaklai M, Rabizadeh E (2004) All three receptors of vascular endothelial growth factor (VEGF) are expressed on B-chronic lymphocytic leukemia (CLL) cells. Leuk Res 28:243\u2013248","journal-title":"Leuk Res"},{"key":"32_CR7","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V99.8.2969","volume":"99","author":"M Barragan","year":"2002","unstructured":"Barragan M, Bellosillo B, Campas C, Colomer D, Pons G, Gil J (2002) Involvement of protein kinase C and phosphatidyl inositole 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99:2969\u20132976","journal-title":"Blood"},{"key":"32_CR8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/eji.1830070702","volume":"7","author":"Y Bergman","year":"1977","unstructured":"Bergman Y, Haimovich J (1977) Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H\/eB origin. Eur J Immunol 7:413\u2013417","journal-title":"Eur J Immunol"},{"key":"32_CR9","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, Russo G, Hardy RR, Croce CM (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99:6955\u20136960","journal-title":"Proc Natl Acad Sci USA"},{"key":"32_CR10","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1038\/sj.leu.2403139","volume":"17","author":"C Billard","year":"2003","unstructured":"Billard C, Kern C, Tang R, Ajchenbaum-Cymbalista F, Kolb JP (2003) Flavopiridol downregulates the expression of both the inducible NO synthetase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia. Leukemia 17:2435\u20132443","journal-title":"Leukemia"},{"key":"32_CR11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0301-472X(02)01076-7","volume":"31","author":"C Bogner","year":"2003","unstructured":"Bogner C, Schneller F, Hipp S, Ringshausen I, Peschel C, Decker T (2003) Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways. Exp Hematol 31:218\u2013225","journal-title":"Exp Hematol"},{"key":"32_CR12","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1517\/14712598.2.2.197","volume":"2","author":"\u00d8 Bruserud","year":"2002","unstructured":"Bruserud \u00d8, Glenjen NI, Gjertsen BT, Herfindal L, D\u00f8skeland SO (2002) Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukemia cells. Expert Opin Biol Ther 2:197\u2013210","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"32_CR13","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","volume":"105","author":"JC Byrd","year":"2004","unstructured":"Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2004) A phase I and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3):959\u2013967","journal-title":"Blood"},{"key":"32_CR14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1517\/13543784.12.6.943","volume":"12","author":"F Caponigro","year":"2003","unstructured":"Caponigro F, Casale M, Bryce I (2003) Farnesyl transferase inhibitors in clinical development. Exp Opin Investig Drugs 12:943\u2013954","journal-title":"Exp Opin Investig Drugs"},{"key":"32_CR15","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1074\/jbc.271.9.4974","volume":"271","author":"C Chavany","year":"1996","unstructured":"Chavany C, Mimnaugh E, Miller P, Bitton R, Nguyen P, Trepel J, Whitesell L, Schnur R, Moyer J, Neckers L (1996) p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2\/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. J Biol Chem 271:4974\u20134977","journal-title":"J Biol Chem"},{"key":"32_CR16","doi-asserted-by":"crossref","unstructured":"Cheson B (2005) Antibody therapy in chronic lymphocytic leukemia. Cancer Immunol Immunother (this issue)","DOI":"10.1007\/s00262-005-0010-0"},{"key":"32_CR17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700544","volume":"10","author":"DP Cioca","year":"2003","unstructured":"Cioca DP, Aoki Y, Kiyosawa K (2003) RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 10:125\u2013133","journal-title":"Cancer Gene Ther"},{"key":"32_CR18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/jnci\/92.13.1042","volume":"92","author":"P Costantini","year":"2000","unstructured":"Costantini P, Jacotot E, Decaudin D, Kroemer G (2000) Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 92:1042\u20131053","journal-title":"J Natl Cancer Inst"},{"key":"32_CR19","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/sj.onc.1206326","volume":"22","author":"G Dewson","year":"2003","unstructured":"Dewson G, Snowden RT, Almond JB, Dyer MJ, Cohen GM (2003) Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells. Oncogene 22:2643\u20132654","journal-title":"Oncogene"},{"key":"32_CR20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/cimm.1997.1149","volume":"179","author":"RS Douglas","year":"1997","unstructured":"Douglas RS, Woo EY, Capocasale RJ, Tarshis AD, Nowell PC, Moore JS (1997) Altered response to and production of TGF-beta by B cells from autoimmune NZB mice. Cell Immunol 179:126\u2013137","journal-title":"Cell Immunol"},{"issue":"suppl 5","key":"32_CR21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.6-suppl_5-4","volume":"6","author":"JL Gabrilove","year":"2001","unstructured":"Gabrilove JL (2001) Angiogenic growth factors: autocrine and paracrine regulation of survival in hematopoietic malignancies. Oncologist 6(suppl 5):4\u20137","journal-title":"Oncologist"},{"key":"32_CR22","first-page":"145","volume":"49","author":"J Gora-Tybor","year":"2002","unstructured":"Gora-Tybor J, Blonski JZ, Robak T (2002) Cladribine decreases the level of angiogenic factors in patients with chronic lymphocytic leukemia. Neoplasma 49:145\u2013148","journal-title":"Neoplasma"},{"key":"32_CR23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1126\/science.1099320","volume":"305","author":"DR Green","year":"2004","unstructured":"Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626\u2013629","journal-title":"Science"},{"key":"32_CR24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1182\/blood.V92.2.368","volume":"92","author":"C Gritti","year":"1998","unstructured":"Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A, Grimber G, Briand P, Sigaux F, Stern MH (1998) Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 92:368\u2013373","journal-title":"Blood"},{"key":"32_CR25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1046\/j.1440-1681.2002.03711.x","volume":"29","author":"DZ Hillyard","year":"2002","unstructured":"Hillyard DZ, Cameron AJM, McIntyre AM, Hadden M, Marshall HE, Johnston N, Jardine AG (2002) Inhibition of proliferation and signalling mechanisms in human lymphocytes by fluvastatin. Clin Exp Pharm Physiol 29:673\u2013678","journal-title":"Clin Exp Pharm Physiol"},{"key":"32_CR26","doi-asserted-by":"crossref","first-page":"14392","DOI":"10.1073\/pnas.212410199","volume":"99","author":"KK Hoyer","year":"2002","unstructured":"Hoyer KK, French SW, Turner DE, Nguyen MT, Renard M, Malone CS, Knoetig S, Qi CF, Su TT, Cheroutre H, Wall R, Rawlings DJ, Morse HC III, Teitell MA (2002) Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma. Proc Natl Acad Sci USA 99:14392\u201314397","journal-title":"Proc Natl Acad Sci USA"},{"key":"32_CR27","doi-asserted-by":"crossref","first-page":"28827","DOI":"10.1074\/jbc.R400012200","volume":"279","author":"Y Huang","year":"2004","unstructured":"Huang Y, Wange RL (2004) T cell receptor signalling: beyond complex complexes. J Biol Chem 279:28827\u201328830","journal-title":"J Biol Chem"},{"key":"32_CR28","first-page":"1370","volume":"10","author":"JL Hummel","year":"1996","unstructured":"Hummel JL, Lichty BD, Reis M, Dube I, Kamel-Reid S (1996) Engraftment of human chronic lymphocytic leukemia cells in SCID mice: in vivo and in vitro studies. Leukemia 10:1370\u20131376","journal-title":"Leukemia"},{"key":"32_CR29","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/blood-2003-05-1603","volume":"103","author":"DT Jones","year":"2004","unstructured":"Jones DT, Addison E, North JM, Lowdell MW, Hoffbrand AV, Mehta AB, Ganeshaguru K, Folarin NI, Wickremasinghe RG (2004) Geldanamycin and Herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells\u2019 sensitivity to cytotoxic drugs. Blood 103:1855\u20131861","journal-title":"Blood"},{"key":"32_CR30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1471-4906(03)00071-1","volume":"24","author":"SB Kanner","year":"2003","unstructured":"Kanner SB, Perez-Villar JJ (2003) Altering T cell activation by targeting the multidomain tyrosine kinase Itk. Trends Immunol 24:249\u2013253","journal-title":"Trends Immunol"},{"key":"32_CR31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0145-2126(93)90154-D","volume":"17","author":"A Kawata","year":"1993","unstructured":"Kawata A, Han T, Dadey B, Weier HU, Okazaki M, Yokota S, Fukiage T, Xiao H, Block AM, Barcos M (1993) Establishment and characterization of the tumors of chronic lymphocytic leukemia cell line in nude and SCID mice. Leuk Res 17:883\u2013894","journal-title":"Leuk Res"},{"key":"32_CR32","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.leu.2402467","volume":"16","author":"NE Kay","year":"2002","unstructured":"Kay NE, Bone ND, Tschumper RC, Howell KH, Geyer SM, Dewald GW, Hanson CA, Jelinek DF (2002) B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16:911\u2013919","journal-title":"Leukemia"},{"key":"32_CR33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.leukres.2003.12.010","volume":"28","author":"TW Kelley","year":"2004","unstructured":"Kelley TW, Alkan S, Srkalovic G, Hsi ED (2004) Treatment of chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res 28:845\u2013850","journal-title":"Leuk Res"},{"key":"32_CR34","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.20696","volume":"101","author":"R Kim","year":"2004","unstructured":"Kim R, Emi M, Tanabe K, Toge T (2004) Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101:2491\u20132502","journal-title":"Cancer"},{"key":"32_CR35","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00062752-200007000-00005","volume":"7","author":"TJ Kipps","year":"2000","unstructured":"Kipps TJ (2000) Chronic lymphocytic leukemia. Curr Opin Hematol 7:223\u2013234","journal-title":"Curr Opin Hematol"},{"key":"32_CR36","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1200\/JCO.2003.09.057","volume":"21","author":"CT Kouroukis","year":"2003","unstructured":"Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM; National Cancer Institute of Canada Clinical Trials Group (2003) Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:1740\u20131745","journal-title":"J Clin Oncol"},{"key":"32_CR37","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/blood-2003-08-2763","volume":"104","author":"YK Lee","year":"2004","unstructured":"Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE (2004) VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocathechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood 104:788\u2013794","journal-title":"Blood"},{"key":"32_CR38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.leu.2400645","volume":"11","author":"H Marcus","year":"1997","unstructured":"Marcus H, Shimoni A, Ergas D, Canaan A, Dekel B, Ben-David D, David M, Sigler E, Reisner Y, Berrebi A (1997) Human\/mouse radiation chimera generated from PBMC of B chronic lymphocytic leukemia patients with autoimmune hemolytic anemia produce anti-human red cell antibodies. Leukemia 11:687\u2013693","journal-title":"Leukemia"},{"key":"32_CR39","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/sj.leu.2403469","volume":"18","author":"I Marzo","year":"2004","unstructured":"Marzo I, Perez-Galan P, Giraldo P, Lopez-Royuela N, Gomez-Benito M, Larrad L, Lasierra P, Rubio-Felix D, Anel A, Naval I (2004) Farnesyl transferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia 18:1599\u20131604","journal-title":"Leukemia"},{"key":"32_CR40","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/10428190009059268","volume":"38","author":"P Masdehors","year":"2000","unstructured":"Masdehors P, Merle-Beral H, Magdelenat H, Delic J (2000) Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma 38:499\u2013504","journal-title":"Leuk Lymphoma"},{"key":"32_CR41","doi-asserted-by":"crossref","unstructured":"Mellstedt H, Choudhury A (2005) T and B cells in chronic lymphocytic leukemia: Faust, Mephistopheles and the pact with the devil. Cancer Immunol Immunother (this issue)","DOI":"10.1007\/s00262-005-0675-4"},{"key":"32_CR42","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00262-003-0423-6","volume":"52","author":"L Mihich","year":"2003","unstructured":"Mihich L (2003) Cellular immunity for cancer chemoimmunotherapy\u2014an overview. Cancer Immunol Immunother 52:661\u2013662","journal-title":"Cancer Immunol Immunother"},{"key":"32_CR43","first-page":"130","volume":"10","author":"RM Mohammad","year":"1996","unstructured":"Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, Abubakr YA, Dugan MC, Al-Katib A (1996) Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 10:130\u2013137","journal-title":"Leukemia"},{"key":"32_CR44","first-page":"1337","volume":"4","author":"RM Mohammad","year":"1998","unstructured":"Mohammad RM, Varterasian ML, Almatchy VP, Hannoudi GN, Pettit GR, Al-Katib A (1998) Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1. Clin Cancer Res 4:1337\u20131343","journal-title":"Clin Cancer Res"},{"key":"32_CR45","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1515\/bchm.1998.379.10.1253","volume":"379","author":"RM Mohammad","year":"1998","unstructured":"Mohammad RM, Beck FW, Katato K, Hamdy N, Wall N, Al-Katib A (1998) Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK\/5\u2019-NT and Bax\/Bcl-1. Biol Chem 379:1253\u20131261","journal-title":"Biol Chem"},{"key":"32_CR46","first-page":"945","volume":"14","author":"RM Mohammed","year":"1999","unstructured":"Mohammed RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, Al-Katib AM (1999) Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine. Int J Oncol 14:945\u2013950","journal-title":"Int J Oncol"},{"key":"32_CR47","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.leukres.2003.08.001","volume":"28","author":"S Molica","year":"2004","unstructured":"Molica S, Vacca A, Levato D, Merchionne F, Ribatti D (2004) Angiogenesis in acute and chronic lymphocytic leukemia. Leukemia Res 28:321\u2013324","journal-title":"Leukemia Res"},{"key":"32_CR48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2407-3-30","volume":"3","author":"JMA Moreira","year":"2003","unstructured":"Moreira JMA, Scheipers P, S\u00f8rensen P (2003) The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3:30","journal-title":"BMC Cancer"},{"key":"32_CR49","doi-asserted-by":"crossref","first-page":"40640","DOI":"10.1074\/jbc.M407576200","volume":"279","author":"A Morinobu","year":"2004","unstructured":"Morinobu A, Kanno Y, O\u2019Sheat JJ (2004) Discrete roles for histone acetylation in human T helper 1 cell-specific gene expression. J Biol Chem 279:40640\u201340646","journal-title":"J Biol Chem"},{"key":"32_CR50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/toxsci\/kfg052","volume":"74","author":"DE Muscarella","year":"2003","unstructured":"Muscarella DE, O\u2019Brien KA, Lemley AT, Bloom SE (2003) Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol Sci 74:66\u201373","journal-title":"Toxicol Sci"},{"key":"32_CR51","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/sj.onc.1201246","volume":"15","author":"MG Narducci","year":"1997","unstructured":"Narducci MG, Virgilio L, Engiles JB, Buchberg AM, Billips L, Facchiano A, Croce CM, Russo G, Rothstein JL (1997) The murine Tcl1 oncogene: embryonic and lymphoid cell expression. Oncogene 15:919\u2013926","journal-title":"Oncogene"},{"issue":"Suppl 4","key":"32_CR52","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S1471-4914(02)02316-X","volume":"8","author":"L Neckers","year":"2002","unstructured":"Neckers L (2002) Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 8(Suppl 4):S55\u2013S61","journal-title":"Trends Mol Med"},{"key":"32_CR53","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Ponisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF (2003) Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 101:1620\u20131629","journal-title":"Blood"},{"key":"32_CR54","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S1097-2765(05)00085-7","volume":"6","author":"K Nishikawa","year":"2000","unstructured":"Nishikawa K, Sawasdikosol S, Fruman DA, Lai J, Songyang Z, Burakoff SJ, Yaffe MB, Cantley LC (2000) A peptide library approach identifies a specific inhibitor for the ZAP-70 protein tyrosine kinase. Mol Cell 6:969\u2013974","journal-title":"Mol Cell"},{"key":"32_CR55","first-page":"338","volume":"10","author":"S O\u2019Brien","year":"1996","unstructured":"O\u2019Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M (1996) Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia 10:338\u2013344","journal-title":"Leukemia"},{"key":"32_CR56","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood.V87.12.5171.bloodjournal87125171","volume":"87","author":"L Ottonello","year":"1996","unstructured":"Ottonello L, Morone P, Dapino P, Dallegri F (1996) Monoclonal Lym-1 antibody-dependent lysis of B-lymphoblastoid tumor targets by human complement and cytokine-exposed mononuclear and neutrophilic polymorphonuclear leukocytes. Blood 87:5171\u20135178","journal-title":"Blood"},{"key":"32_CR57","first-page":"4570","volume":"9","author":"JC Pahler","year":"2003","unstructured":"Pahler JC, Ruiz S, Niemer I, Calvert LR, Andreeff M, Keating M, Faderl S, McConkey DJ (2003) Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Clin Cancer Res 9:4570\u20134577","journal-title":"Clin Cancer Res"},{"key":"32_CR58","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4049\/jimmunol.153.4.1869","volume":"153","author":"B Peng","year":"1994","unstructured":"Peng B, Sherr DH, Mahboudi F, Hardin J, Wu YH, Sharer L, Raveche ES (1994) A cultured malignant B-1 line serves as a model for Richter\u2019s syndrome. J Immunol 153:1869\u20131880","journal-title":"J Immunol"},{"key":"32_CR59","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/10428199809092690","volume":"28","author":"C Pepper","year":"1998","unstructured":"Pepper C, Hoy T, Bentley P (1998) Elevated Bcl-2\/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 28:355\u2013361","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"32_CR60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/1042819021000029984","volume":"44","author":"C Pepper","year":"2003","unstructured":"Pepper C, Thomas A, Fegan C, Hoy T, Bentley P (2003) Flavopiridol induces apoptosis in B-cell chronic lymphocytic leukaemia cells through a p38 and ERK MAP kinase-dependent mechanism. Leuk Lymphoma 44(2):337\u2013342","journal-title":"Leuk Lymphoma"},{"key":"32_CR61","first-page":"437","volume":"52","author":"JA Phillips","year":"1992","unstructured":"Phillips JA, Mehta K, Fernandez C, Raveche ES (1992) The NZB mouse as a model for chronic lymphocytic leukemia. Cancer Res 52:437\u2013443","journal-title":"Cancer Res"},{"key":"32_CR62","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2004.10.037","volume":"22","author":"S Rao","year":"2004","unstructured":"Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruixo JJ, Park YC, Palmer PA (2004) Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950\u20133957","journal-title":"J Clin Oncol"},{"key":"32_CR63","doi-asserted-by":"crossref","unstructured":"Ravandi F, O\u2019Brien S (2005) Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother (this issue)","DOI":"10.1007\/s00262-005-0015-8"},{"key":"32_CR64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0090-1229(90)90136-E","volume":"56","author":"ES Raveche","year":"1990","unstructured":"Raveche ES (1990) Possible immunoregulatory role for CD5+ B cells. Clin Immunol Immunopathol 56:135\u2013150","journal-title":"Clin Immunol Immunopathol"},{"key":"32_CR65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/cimm.1998.1319","volume":"187","author":"E Raveche","year":"1998","unstructured":"Raveche E, Fernandes H, Ong H, Peng B (1998) Regulatory role of T cells in a murine model of lymphoproliferative disease. Cell Immunol 187:67\u201375","journal-title":"Cell Immunol"},{"key":"32_CR66","first-page":"11","volume":"25","author":"JC Reed","year":"1998","unstructured":"Reed JC (1998) Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11\u201318","journal-title":"Semin Oncol"},{"key":"32_CR67","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/sj.leu.2402970","volume":"17","author":"D Ribatti","year":"2003","unstructured":"Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, Roccaro AM, Dammacco F (2003) Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia 17:1428\u20131430","journal-title":"Leukemia"},{"key":"32_CR68","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609\u20132617","journal-title":"N Engl J Med"},{"key":"32_CR69","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/0008-5472.CAN-03-2870","volume":"64","author":"LJ Rush","year":"2004","unstructured":"Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C (2004) Epigenetic profiling of chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 64:2424\u20132433","journal-title":"Cancer Res"},{"key":"32_CR70","first-page":"2228","volume":"7","author":"EA Sausville","year":"2001","unstructured":"Sausville EA (2001) Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 7:2228\u20132236","journal-title":"Clin Cancer Res"},{"key":"32_CR71","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1600-0609.2003.00087.x","volume":"71","author":"EM Schiavone","year":"2003","unstructured":"Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D\u2019Amico MR, Vecchio LD, Ferrara F (2003) Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol 71:23\u201328","journal-title":"Eur J Haematol"},{"key":"32_CR72","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.1038\/sj.onc.1204121","volume":"19","author":"SM Sebti","year":"2000","unstructured":"Sebti SM, Hamilton AD (2000) Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 19:6566\u20136573","journal-title":"Oncogene"},{"key":"32_CR73","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1084\/jem.166.5.1585","volume":"166","author":"MF Seldin","year":"1987","unstructured":"Seldin MF, Conroy J, Steinberg AD, D\u2019Hoosteleare LA, Raveche ES (1987) Clonal expansion of abnormal B cells in old NZB mice. J Exp Med 166:1585\u20131590","journal-title":"J Exp Med"},{"key":"32_CR74","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","volume":"89","author":"ZX Shen","year":"1997","unstructured":"Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354\u20133360","journal-title":"Blood"},{"key":"32_CR75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1034\/j.1600-0609.2003.00087.x","volume":"71","author":"EM Schiavone","year":"2003","unstructured":"Schiavone EM, De Simone M, Palmieri S, Annunziata M, Pocali B, Copia C, D\u2019Amico MR, Vecchio LD, Ferrara F (2003) Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. Eur J Haematol 71:23\u201328","journal-title":"Eur J Haematol"},{"key":"32_CR76","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1182\/blood.V89.6.2210","volume":"89","author":"A Shimoni","year":"1997","unstructured":"Shimoni A, Marcus H, Canaan A, Ergas D, David M, Berrebi A, Reisner Y (1997) A model for human B-chronic lymphocytic leukemia in human\/mouse radiation chimera: evidence for tumor-mediated suppression of antibody production in low-stage disease. Blood 89:2210\u20132218","journal-title":"Blood"},{"key":"32_CR77","first-page":"5968","volume":"59","author":"A Shimoni","year":"1999","unstructured":"Shimoni A, Marcus H, Dekel B, Shkarchi R, Arditti F, Shvidel L, Shtalrid M, Bucher W, Canaan A, Ergas D, Berrebi A, Reisner Y (1999) Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human\u2013>mouse radiation chimera. Cancer Res 59:5968\u20135974","journal-title":"Cancer Res"},{"key":"32_CR78","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/272624a0","volume":"272","author":"S Slavin","year":"1978","unstructured":"Slavin S, Strober S (1978) Spontaneous murine B-cell leukaemia. Nature 272:624\u2013626","journal-title":"Nature"},{"key":"32_CR79","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800050998","volume":"44","author":"SL Soignet","year":"1999","unstructured":"Soignet SL, Tong WP, Hirschfeld S, Warrell RP, Jr (1999) Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 44:417\u2013421","journal-title":"Cancer Chemother Pharmacol"},{"key":"32_CR80","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.imlet.2003.11.025","volume":"92","author":"AS Sreedhar","year":"2004","unstructured":"Sreedhar AS, Nardai G, Csermerel P (2004) Enhancement of complement-induced lysis: a novel mechanism for the anti-cancer effects of Hsp90 inhibitors. Immunol Lett 92:157\u2013161","journal-title":"Immunol Lett"},{"key":"32_CR81","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S0301-472X(01)00690-7","volume":"29","author":"YC Su","year":"2001","unstructured":"Su YC, Wu WM, Wu MF, Chiang BL (2001) A model of chronic lymphocytic leukemia with Richter\u2019s transformation in severe combined immunodeficiency mice. Exp Hematol 29:1218\u20131225","journal-title":"Exp Hematol"},{"key":"32_CR82","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1517\/14728222.7.5.663","volume":"7","author":"KJ Tronstad","year":"2003","unstructured":"Tronstad KJ, Berge K, Berge RK, Bruserud \u00d8 (2003) Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin Ther Targets 7:663\u2013677","journal-title":"Expert Opin Ther Targets"},{"key":"32_CR83","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1074-5521(03)00142-X","volume":"10","author":"KJ Tronstad","year":"2003","unstructured":"Tronstad KJ, Gjertsen BT, Krakstad C, Berge K, Brustugun OT, Doskeland SO, Berge RK (2003) Mitochondrial-targeted fatty acid analog induces apoptosis with selective loss of mitochondrial glutathione in promyelocytic leukemia cells. Chem Biol 10:609\u2013618","journal-title":"Chem Biol"},{"key":"32_CR84","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1002\/cncr.20252","volume":"100","author":"AM Tsimberidou","year":"2004","unstructured":"Tsimberidou AM, Murray JL, O\u2019Brien S, Wierda WG, Keating MJ (2004) Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer 100:2195\u20132200","journal-title":"Cancer"},{"key":"32_CR85","doi-asserted-by":"crossref","first-page":"8324","DOI":"10.1073\/pnas.91.18.8324","volume":"91","author":"L Whitesell","year":"1994","unstructured":"Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM (1994) Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324\u20138328","journal-title":"Proc Natl Acad Sci USA"},{"key":"32_CR86","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1034\/j.1600-6143.2002.21006.x","volume":"2","author":"J Wu","year":"2002","unstructured":"Wu J (2002) On the role of proteasomes in cell biology and proteasome inhibition as a novel frontier in the development of immunosupresants. Am J Transplant 2:904\u2013912","journal-title":"Am J Transplant"},{"key":"32_CR87","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","volume":"101","author":"Y Zhou","year":"2003","unstructured":"Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P (2003) Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101:4098\u20134104","journal-title":"Blood"},{"key":"32_CR88","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/1568009054064651","volume":"5","author":"KJ Hatfield","year":"2005","unstructured":"Hatfield KJ, Olsnes AM, Gjertsen BT, Bruserud \u00d8 (2005) Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets 5:229\u2013248","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-005-0032-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-005-0032-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T23:46:06Z","timestamp":1706399166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-005-0032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,21]]},"references-count":88,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["32"],"URL":"https:\/\/doi.org\/10.1007\/s00262-005-0032-7","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2005,7,21]]}}}